| Assay ID | Title | Year | Journal | Article |
|---|
| AID1347097 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1296008 | Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening | 2020 | SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
| Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening. |
| AID1347101 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347089 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347154 | Primary screen GU AMC qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
| Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1347106 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347096 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347107 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347094 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347100 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347083 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1346986 | P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5
| A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1347098 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347099 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347102 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347093 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1346987 | P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5
| A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1347091 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | | | |
| AID1347104 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347103 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1508630 | Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay | 2021 | Cell reports, 04-27, Volume: 35, Issue:4
| A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome. |
| AID1347090 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347082 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1347092 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347108 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347095 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347105 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347086 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1347157 | Confirmatory screen GU Rhodamine qHTS for Zika virus inhibitors qHTS | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
| Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1347160 | Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
| Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1347164 | 384 well plate NINDS Rhodamine confirmatory qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
| Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1347161 | Confirmatory screen NINDS Rhodamine qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
| Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1347163 | 384 well plate NINDS AMC confirmatory qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
| Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1347411 | qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary | 2020 | ACS chemical biology, 07-17, Volume: 15, Issue:7
| High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle. |
| AID1347169 | Tertiary RLuc qRT-PCR qHTS assay for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
| Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1347159 | Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
| Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID692234 | Ratio drug uptake in liver to plasma of female rhesus monkey at 5 mg/kg, po measured 6 hrs post dose | 2011 | Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
| Development of a liver-targeted stearoyl-CoA desaturase (SCD) inhibitor (MK-8245) to establish a therapeutic window for the treatment of diabetes and dyslipidemia. |
| AID640645 | Drug level in plasma of C57BL/6 mouse at 10 mg/kg, po measured 6 hrs post dosing | 2012 | Bioorganic & medicinal chemistry letters, Jan-15, Volume: 22, Issue:2
| Discovery of potent and liver-targeted stearoyl-CoA desaturase (SCD) inhibitors in a bispyrrolidine series. |
| AID692220 | Drug uptake in eye of female rhesus monkey at 5 mg/kg, po measured 6 hrs post dose | 2011 | Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
| Development of a liver-targeted stearoyl-CoA desaturase (SCD) inhibitor (MK-8245) to establish a therapeutic window for the treatment of diabetes and dyslipidemia. |
| AID692429 | Transport by human OATP1B1 stably transfected in butyrate treated dog MDCK2 cells at 10 uM after 3 hrs by scintillation counting in presence of 100 uM OATP inhibitor sulfobromophthalein | 2011 | Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
| Development of a liver-targeted stearoyl-CoA desaturase (SCD) inhibitor (MK-8245) to establish a therapeutic window for the treatment of diabetes and dyslipidemia. |
| AID692207 | Inhibition of human delta6 desaturase activity expressed in human HEpG2 cells | 2011 | Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
| Development of a liver-targeted stearoyl-CoA desaturase (SCD) inhibitor (MK-8245) to establish a therapeutic window for the treatment of diabetes and dyslipidemia. |
| AID692206 | Inhibition of rat delta-6 desaturase activity expressed in human HEpG2 cells | 2011 | Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
| Development of a liver-targeted stearoyl-CoA desaturase (SCD) inhibitor (MK-8245) to establish a therapeutic window for the treatment of diabetes and dyslipidemia. |
| AID692226 | Ratio drug uptake in liver to skin of female rhesus monkey at 5 mg/kg, po measured 6 hrs post dose | 2011 | Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
| Development of a liver-targeted stearoyl-CoA desaturase (SCD) inhibitor (MK-8245) to establish a therapeutic window for the treatment of diabetes and dyslipidemia. |
| AID647878 | Drug uptake in mouse shaved skin at 10 mg/kg, po after 6 hrs | 2012 | Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1
| Discovery of potent and liver-selective stearoyl-CoA desaturase (SCD) inhibitors in an acyclic linker series. |
| AID692479 | Inhibition of SCD-1 activity in human Hepatocytes expressing organic anion transporting polypeptides assessed as reduction in [I-14C] stearoyl CoA desaturation after 1 hr by scintillation counting | 2011 | Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
| Development of a liver-targeted stearoyl-CoA desaturase (SCD) inhibitor (MK-8245) to establish a therapeutic window for the treatment of diabetes and dyslipidemia. |
| AID692230 | Ratio drug uptake in liver to harderian gland of female rhesus monkey at 5 mg/kg, po measured 6 hrs post dose | 2011 | Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
| Development of a liver-targeted stearoyl-CoA desaturase (SCD) inhibitor (MK-8245) to establish a therapeutic window for the treatment of diabetes and dyslipidemia. |
| AID692480 | Antidiabetic activity in diet-induced obese C57BL6 mouse assessed as reduction in liver steatosis at 20 to 60 mg/kg, po BID measured on day 28 | 2011 | Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
| Development of a liver-targeted stearoyl-CoA desaturase (SCD) inhibitor (MK-8245) to establish a therapeutic window for the treatment of diabetes and dyslipidemia. |
| AID692456 | Antidiabetic activity in diet-induced obese C57BL6 mouse assessed as reduction in liver triglyceride level at 20 mg/kg, po BID | 2011 | Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
| Development of a liver-targeted stearoyl-CoA desaturase (SCD) inhibitor (MK-8245) to establish a therapeutic window for the treatment of diabetes and dyslipidemia. |
| AID692472 | Inhibition of SCD activity in liver of diet-induced obese C57BL6 mouse assessed as reduction in desaturation induces at 20 mg/kg, po BID administered for 4 weeks | 2011 | Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
| Development of a liver-targeted stearoyl-CoA desaturase (SCD) inhibitor (MK-8245) to establish a therapeutic window for the treatment of diabetes and dyslipidemia. |
| AID692221 | Drug uptake in liver of Beagle dog at 5 mg/kg, po measured 6 hrs post dose | 2011 | Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
| Development of a liver-targeted stearoyl-CoA desaturase (SCD) inhibitor (MK-8245) to establish a therapeutic window for the treatment of diabetes and dyslipidemia. |
| AID692453 | Antidiabetic activity in diet-induced obese C57BL6 mouse assessed as reduction in body weight gain at 20 mg/kg, po BID | 2011 | Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
| Development of a liver-targeted stearoyl-CoA desaturase (SCD) inhibitor (MK-8245) to establish a therapeutic window for the treatment of diabetes and dyslipidemia. |
| AID692203 | Inhibition of mouse SCD-1 | 2011 | Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
| Development of a liver-targeted stearoyl-CoA desaturase (SCD) inhibitor (MK-8245) to establish a therapeutic window for the treatment of diabetes and dyslipidemia. |
| AID640646 | Drug level in harderian gland of C57BL/6 mouse at 10 mg/kg, po measured 6 hrs post dosing | 2012 | Bioorganic & medicinal chemistry letters, Jan-15, Volume: 22, Issue:2
| Discovery of potent and liver-targeted stearoyl-CoA desaturase (SCD) inhibitors in a bispyrrolidine series. |
| AID692475 | Drug level in harderian gland of diet-induced obese C57BL6 mouse at 20 mg/kg, po BID | 2011 | Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
| Development of a liver-targeted stearoyl-CoA desaturase (SCD) inhibitor (MK-8245) to establish a therapeutic window for the treatment of diabetes and dyslipidemia. |
| AID692211 | Oral bioavailability in dog | 2011 | Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
| Development of a liver-targeted stearoyl-CoA desaturase (SCD) inhibitor (MK-8245) to establish a therapeutic window for the treatment of diabetes and dyslipidemia. |
| AID692237 | Transport mediated by human OATP1B3 stably transfected in butyrate treated dog MDCK2 cells at 10 uM after 3 hrs by scintillation counting | 2011 | Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
| Development of a liver-targeted stearoyl-CoA desaturase (SCD) inhibitor (MK-8245) to establish a therapeutic window for the treatment of diabetes and dyslipidemia. |
| AID692227 | Ratio drug uptake in liver to skin of Beagle dog at 5 mg/kg, po measured 6 hrs post dose | 2011 | Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
| Development of a liver-targeted stearoyl-CoA desaturase (SCD) inhibitor (MK-8245) to establish a therapeutic window for the treatment of diabetes and dyslipidemia. |
| AID692222 | Drug uptake in skin of Beagle dog at 5 mg/kg, po measured 6 hrs post dose | 2011 | Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
| Development of a liver-targeted stearoyl-CoA desaturase (SCD) inhibitor (MK-8245) to establish a therapeutic window for the treatment of diabetes and dyslipidemia. |
| AID647872 | Inhibition of SCD1 in mouse liver assessed as reduction in conversion of [14C]stearic acid to [14C]oleic acid at 2 mg/kg, po measured after 3 hrs | 2012 | Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1
| Discovery of potent and liver-selective stearoyl-CoA desaturase (SCD) inhibitors in an acyclic linker series. |
| AID692202 | Inhibition of rat SCD-1 | 2011 | Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
| Development of a liver-targeted stearoyl-CoA desaturase (SCD) inhibitor (MK-8245) to establish a therapeutic window for the treatment of diabetes and dyslipidemia. |
| AID640644 | Drug level in liver of C57BL/6 mouse at 10 mg/kg, po measured 6 hrs post dosing | 2012 | Bioorganic & medicinal chemistry letters, Jan-15, Volume: 22, Issue:2
| Discovery of potent and liver-targeted stearoyl-CoA desaturase (SCD) inhibitors in a bispyrrolidine series. |
| AID692215 | Drug uptake in liver of Sprague-Dawley rat at 10 mg/kg, po measured 6 hrs post dose | 2011 | Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
| Development of a liver-targeted stearoyl-CoA desaturase (SCD) inhibitor (MK-8245) to establish a therapeutic window for the treatment of diabetes and dyslipidemia. |
| AID692431 | Antidiabetic activity in po dosed diet-induced obese fasted C57BL6 mouse assessed as increase in glucose clearance administered 1 hr before glucose challenge measured 12 hrs thereafter by OGTT | 2011 | Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
| Development of a liver-targeted stearoyl-CoA desaturase (SCD) inhibitor (MK-8245) to establish a therapeutic window for the treatment of diabetes and dyslipidemia. |
| AID692225 | Ratio drug uptake in liver to skin of Sprague-Dawley rat at 10 mg/kg, po measured 6 hrs post dose | 2011 | Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
| Development of a liver-targeted stearoyl-CoA desaturase (SCD) inhibitor (MK-8245) to establish a therapeutic window for the treatment of diabetes and dyslipidemia. |
| AID692223 | Drug uptake in eye of Beagle dog at 5 mg/kg, po measured 6 hrs post dose | 2011 | Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
| Development of a liver-targeted stearoyl-CoA desaturase (SCD) inhibitor (MK-8245) to establish a therapeutic window for the treatment of diabetes and dyslipidemia. |
| AID692231 | Ratio drug uptake in liver to harderian gland of Beagle dog at 5 mg/kg, po measured 6 hrs post dose | 2011 | Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
| Development of a liver-targeted stearoyl-CoA desaturase (SCD) inhibitor (MK-8245) to establish a therapeutic window for the treatment of diabetes and dyslipidemia. |
| AID692219 | Drug uptake in skin of female rhesus monkey at 5 mg/kg, po measured 6 hrs post dose | 2011 | Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
| Development of a liver-targeted stearoyl-CoA desaturase (SCD) inhibitor (MK-8245) to establish a therapeutic window for the treatment of diabetes and dyslipidemia. |
| AID640639 | Antidiabetic activity in C57BL/6 mouse LPD model assessed as reduction in liver SCD activity at 1.6 uM liver concentration dosed at 0.4 mg/kg, po measured 3 hrs post dosing | 2012 | Bioorganic & medicinal chemistry letters, Jan-15, Volume: 22, Issue:2
| Discovery of potent and liver-targeted stearoyl-CoA desaturase (SCD) inhibitors in a bispyrrolidine series. |
| AID692463 | Toxicity in diet-induced obese C57BL6 mouse assessed as adverse effect in eye at 20 to 60 mg/kg, po BID measured within 4 weeks | 2011 | Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
| Development of a liver-targeted stearoyl-CoA desaturase (SCD) inhibitor (MK-8245) to establish a therapeutic window for the treatment of diabetes and dyslipidemia. |
| AID692218 | Drug uptake in liver of female rhesus monkey at 5 mg/kg, po measured 6 hrs post dose | 2011 | Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
| Development of a liver-targeted stearoyl-CoA desaturase (SCD) inhibitor (MK-8245) to establish a therapeutic window for the treatment of diabetes and dyslipidemia. |
| AID692208 | Apparent permeability across pig LLC-PK1 cells | 2011 | Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
| Development of a liver-targeted stearoyl-CoA desaturase (SCD) inhibitor (MK-8245) to establish a therapeutic window for the treatment of diabetes and dyslipidemia. |
| AID692435 | Antidiabetic activity in diet-induced obese C57BL6 mouse assessed as reduction in glucose AUC at 3 to 7 mg/kg, po administered 1 hr before oral glucose administration measured 2 hrs thereafter | 2011 | Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
| Development of a liver-targeted stearoyl-CoA desaturase (SCD) inhibitor (MK-8245) to establish a therapeutic window for the treatment of diabetes and dyslipidemia. |
| AID692216 | Drug uptake in skin of Sprague-Dawley rat at 10 mg/kg, po measured 6 hrs post dose | 2011 | Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
| Development of a liver-targeted stearoyl-CoA desaturase (SCD) inhibitor (MK-8245) to establish a therapeutic window for the treatment of diabetes and dyslipidemia. |
| AID692204 | Inhibition of rat delta-5 desaturase activity expressed in human HEpG2 cells | 2011 | Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
| Development of a liver-targeted stearoyl-CoA desaturase (SCD) inhibitor (MK-8245) to establish a therapeutic window for the treatment of diabetes and dyslipidemia. |
| AID692430 | Transport by human OATP1B3 stably transfected in butyrate treated dog MDCK2 cells at 10 uM after 3 hrs by scintillation counting in presence of 100 uM OATP inhibitor sulfobromophthalein | 2011 | Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
| Development of a liver-targeted stearoyl-CoA desaturase (SCD) inhibitor (MK-8245) to establish a therapeutic window for the treatment of diabetes and dyslipidemia. |
| AID692477 | Ratio drug uptake in liver to harderian gland in diet-induced C57BL6 mouse at 20 mg/kg, po measured after 4 weeks of dosing | 2011 | Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
| Development of a liver-targeted stearoyl-CoA desaturase (SCD) inhibitor (MK-8245) to establish a therapeutic window for the treatment of diabetes and dyslipidemia. |
| AID640650 | Antidiabetic activity in po dosed C57BL/6 mouse LPD model assessed as reduction in liver SCD activity measured 6 hrs post dosing | 2012 | Bioorganic & medicinal chemistry letters, Jan-15, Volume: 22, Issue:2
| Discovery of potent and liver-targeted stearoyl-CoA desaturase (SCD) inhibitors in a bispyrrolidine series. |
| AID647881 | Inhibition of SCD1 in mouse liver assessed as reduction in conversion of [14C]stearic acid to [14C]oleic acid after at 0.4 mg/kg, po after 3 hrs | 2012 | Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1
| Discovery of potent and liver-selective stearoyl-CoA desaturase (SCD) inhibitors in an acyclic linker series. |
| AID692224 | Ratio drug uptake in liver to skin of C57BL6 mouse at 10 mg/kg, po measured 6 hrs post dose | 2011 | Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
| Development of a liver-targeted stearoyl-CoA desaturase (SCD) inhibitor (MK-8245) to establish a therapeutic window for the treatment of diabetes and dyslipidemia. |
| AID692459 | Toxicity in diet-induced obese C57BL6 mouse assessed as reduction in food intake at 20 to 60 mg/kg, po BID | 2011 | Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
| Development of a liver-targeted stearoyl-CoA desaturase (SCD) inhibitor (MK-8245) to establish a therapeutic window for the treatment of diabetes and dyslipidemia. |
| AID692233 | Ratio drug uptake in liver to plasma of Sprague-Dawley rat at 10 mg/kg, po measured 6 hrs post dose | 2011 | Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
| Development of a liver-targeted stearoyl-CoA desaturase (SCD) inhibitor (MK-8245) to establish a therapeutic window for the treatment of diabetes and dyslipidemia. |
| AID692236 | Transport mediated by human OATP1B1 butyrate treated stably transfected in dog MDCK2 cells at 10 uM after 3 hrs by scintillation counting | 2011 | Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
| Development of a liver-targeted stearoyl-CoA desaturase (SCD) inhibitor (MK-8245) to establish a therapeutic window for the treatment of diabetes and dyslipidemia. |
| AID692457 | Antidiabetic activity in diet-induced obese C57BL6 mouse assessed as reduction in liver triglyceride level at 60 mg/kg, po BID | 2011 | Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
| Development of a liver-targeted stearoyl-CoA desaturase (SCD) inhibitor (MK-8245) to establish a therapeutic window for the treatment of diabetes and dyslipidemia. |
| AID692232 | Ratio drug uptake in liver to plasma of C57BL6 mouse at 10 mg/kg, po measured 6 hrs post dose | 2011 | Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
| Development of a liver-targeted stearoyl-CoA desaturase (SCD) inhibitor (MK-8245) to establish a therapeutic window for the treatment of diabetes and dyslipidemia. |
| AID692205 | Inhibition of human delta-5 desaturase activity expressed in human HEpG2 cells | 2011 | Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
| Development of a liver-targeted stearoyl-CoA desaturase (SCD) inhibitor (MK-8245) to establish a therapeutic window for the treatment of diabetes and dyslipidemia. |
| AID640648 | Ratio of drug uptake in liver to harderian gland of C57BL/6 mouse at 10 mg/kg, po measured 6 hrs post dosing | 2012 | Bioorganic & medicinal chemistry letters, Jan-15, Volume: 22, Issue:2
| Discovery of potent and liver-targeted stearoyl-CoA desaturase (SCD) inhibitors in a bispyrrolidine series. |
| AID647879 | Drug uptake in mouse harderian glands at 10 mg/kg, po after 6 hrs | 2012 | Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1
| Discovery of potent and liver-selective stearoyl-CoA desaturase (SCD) inhibitors in an acyclic linker series. |
| AID692476 | Ratio drug uptake in liver to harderian gland in diet-induced C57BL6 mouse at 20 mg/kg, po measured after single dose | 2011 | Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
| Development of a liver-targeted stearoyl-CoA desaturase (SCD) inhibitor (MK-8245) to establish a therapeutic window for the treatment of diabetes and dyslipidemia. |
| AID692200 | Ratio IC50 for SCD-1 activity in organic anion transporting polypeptides-deficient human HepG2 cells to IC50 for SCD-1 activity in Sprague-Dawley rat Hepatocytes expressing organic anion transporting polypeptides | 2011 | Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
| Development of a liver-targeted stearoyl-CoA desaturase (SCD) inhibitor (MK-8245) to establish a therapeutic window for the treatment of diabetes and dyslipidemia. |
| AID692478 | Ratio drug uptake in liver to harderian gland in diet-induced C57BL6 mouse at 20 mg/kg, po measured after 1 weeks of dosing | 2011 | Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
| Development of a liver-targeted stearoyl-CoA desaturase (SCD) inhibitor (MK-8245) to establish a therapeutic window for the treatment of diabetes and dyslipidemia. |
| AID692229 | Ratio drug uptake in liver to harderian gland of Sprague-Dawley rat at 10 mg/kg, po measured 6 hrs post dose | 2011 | Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
| Development of a liver-targeted stearoyl-CoA desaturase (SCD) inhibitor (MK-8245) to establish a therapeutic window for the treatment of diabetes and dyslipidemia. |
| AID692209 | Oral bioavailability in mouse | 2011 | Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
| Development of a liver-targeted stearoyl-CoA desaturase (SCD) inhibitor (MK-8245) to establish a therapeutic window for the treatment of diabetes and dyslipidemia. |
| AID692473 | Inhibition of SCD activity in harderian gland of diet-induced obese C57BL6 mouse assessed as reduction in desaturation induces at 20 mg/kg, po BID administered for 4 weeks | 2011 | Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
| Development of a liver-targeted stearoyl-CoA desaturase (SCD) inhibitor (MK-8245) to establish a therapeutic window for the treatment of diabetes and dyslipidemia. |
| AID647877 | Drug uptake in mouse plasma at 10 mg/kg, po after 6 hrs | 2012 | Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1
| Discovery of potent and liver-selective stearoyl-CoA desaturase (SCD) inhibitors in an acyclic linker series. |
| AID692462 | Toxicity in diet-induced obese C57BL6 mouse assessed as adverse effect in skin at 20 to 60 mg/kg, po BID measured within 4 weeks | 2011 | Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
| Development of a liver-targeted stearoyl-CoA desaturase (SCD) inhibitor (MK-8245) to establish a therapeutic window for the treatment of diabetes and dyslipidemia. |
| AID692235 | Ratio drug uptake in liver to plasma of Beagle dog at 5 mg/kg, po measured 6 hrs post dose | 2011 | Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
| Development of a liver-targeted stearoyl-CoA desaturase (SCD) inhibitor (MK-8245) to establish a therapeutic window for the treatment of diabetes and dyslipidemia. |
| AID692199 | Inhibition of SCD-1 activity in Sprague-Dawley rat Hepatocytes expressing organic anion transporting polypeptides assessed as reduction in [I-14C] stearoyl CoA desaturation by scintillation counting | 2011 | Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
| Development of a liver-targeted stearoyl-CoA desaturase (SCD) inhibitor (MK-8245) to establish a therapeutic window for the treatment of diabetes and dyslipidemia. |
| AID640647 | Ratio of drug uptake in liver to plasma of C57BL/6 mouse at 10 mg/kg, po measured 6 hrs post dosing | 2012 | Bioorganic & medicinal chemistry letters, Jan-15, Volume: 22, Issue:2
| Discovery of potent and liver-targeted stearoyl-CoA desaturase (SCD) inhibitors in a bispyrrolidine series. |
| AID640638 | Antidiabetic activity in C57BL/6 mouse LPD model assessed as reduction in liver SCD activity at 4.9 uM liver concentration dosed at 2 mg/kg, po measured 3 hrs post dosing | 2012 | Bioorganic & medicinal chemistry letters, Jan-15, Volume: 22, Issue:2
| Discovery of potent and liver-targeted stearoyl-CoA desaturase (SCD) inhibitors in a bispyrrolidine series. |
| AID692197 | Inhibition of SCD-1 activity in Sprague-Dawley rat microsome assessed as reduction in [I-14C] stearoyl CoA desaturation by scintillation counting | 2011 | Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
| Development of a liver-targeted stearoyl-CoA desaturase (SCD) inhibitor (MK-8245) to establish a therapeutic window for the treatment of diabetes and dyslipidemia. |
| AID692474 | Drug level in liver of diet-induced obese C57BL6 mouse at 20 mg/kg, po BID | 2011 | Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
| Development of a liver-targeted stearoyl-CoA desaturase (SCD) inhibitor (MK-8245) to establish a therapeutic window for the treatment of diabetes and dyslipidemia. |
| AID647882 | Drug uptake in mouse liver at 0.4 mg/kg, po after 3 hrs | 2012 | Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1
| Discovery of potent and liver-selective stearoyl-CoA desaturase (SCD) inhibitors in an acyclic linker series. |
| AID692212 | Drug uptake in liver of C57BL6 mouse at 10 mg/kg, po measured 6 hrs post dose | 2011 | Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
| Development of a liver-targeted stearoyl-CoA desaturase (SCD) inhibitor (MK-8245) to establish a therapeutic window for the treatment of diabetes and dyslipidemia. |
| AID692436 | Antidiabetic activity in diet-induced obese C57BL6 mouse assessed as reduction in glucose AUC at 7 to 10 mg/kg, po administered 1 hr before oral glucose administration measured 2 hrs thereafter | 2011 | Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
| Development of a liver-targeted stearoyl-CoA desaturase (SCD) inhibitor (MK-8245) to establish a therapeutic window for the treatment of diabetes and dyslipidemia. |
| AID692454 | Antidiabetic activity in diet-induced obese C57BL6 mouse assessed as reduction in body weight gain at 60 mg/kg, po BID | 2011 | Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
| Development of a liver-targeted stearoyl-CoA desaturase (SCD) inhibitor (MK-8245) to establish a therapeutic window for the treatment of diabetes and dyslipidemia. |
| AID692437 | Antidiabetic activity in diet-induced obese C57BL6 mouse assessed as reduction in glucose AUC at 7 to 30 mg/kg, po administered 1 hr before oral glucose administration measured 2 hrs thereafter | 2011 | Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
| Development of a liver-targeted stearoyl-CoA desaturase (SCD) inhibitor (MK-8245) to establish a therapeutic window for the treatment of diabetes and dyslipidemia. |
| AID692213 | Drug uptake in skin of C57BL6 mouse at 10 mg/kg, po measured 6 hrs post dose | 2011 | Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
| Development of a liver-targeted stearoyl-CoA desaturase (SCD) inhibitor (MK-8245) to establish a therapeutic window for the treatment of diabetes and dyslipidemia. |
| AID692210 | Oral bioavailability in rat | 2011 | Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
| Development of a liver-targeted stearoyl-CoA desaturase (SCD) inhibitor (MK-8245) to establish a therapeutic window for the treatment of diabetes and dyslipidemia. |
| AID647876 | Drug metabolism in rat hepatocytes assessed as 2-(5-(3-amino-3-(4-(2-bromo-5-fluorophenoxy)piperidin-1-yl)acryloyl)-2H-tetrazol-2-yl)acetic acid level | 2012 | Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1
| Discovery of potent and liver-selective stearoyl-CoA desaturase (SCD) inhibitors in an acyclic linker series. |
| AID640649 | Inhibition of mouse SCD-1 | 2012 | Bioorganic & medicinal chemistry letters, Jan-15, Volume: 22, Issue:2
| Discovery of potent and liver-targeted stearoyl-CoA desaturase (SCD) inhibitors in a bispyrrolidine series. |
| AID692217 | Drug uptake in eye of Sprague-Dawley rat at 10 mg/kg, po measured 6 hrs post dose | 2011 | Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
| Development of a liver-targeted stearoyl-CoA desaturase (SCD) inhibitor (MK-8245) to establish a therapeutic window for the treatment of diabetes and dyslipidemia. |
| AID692198 | Inhibition of SCD-1 activity in organic anion transporting polypeptides-deficient human HepG2 cells assessed as reduction in [I-14C] stearoyl CoA desaturation by scintillation counting | 2011 | Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
| Development of a liver-targeted stearoyl-CoA desaturase (SCD) inhibitor (MK-8245) to establish a therapeutic window for the treatment of diabetes and dyslipidemia. |
| AID647867 | Drug uptake in mouse liver at 10 mg/kg, po after 6 hrs | 2012 | Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1
| Discovery of potent and liver-selective stearoyl-CoA desaturase (SCD) inhibitors in an acyclic linker series. |
| AID692201 | Inhibition of human SCD-1 | 2011 | Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
| Development of a liver-targeted stearoyl-CoA desaturase (SCD) inhibitor (MK-8245) to establish a therapeutic window for the treatment of diabetes and dyslipidemia. |
| AID647857 | Inhibition of SCD1 in OATP-deficient human HepG2 cells by whole cell assay | 2012 | Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1
| Discovery of potent and liver-selective stearoyl-CoA desaturase (SCD) inhibitors in an acyclic linker series. |
| AID647873 | Drug uptake in mouse liver at 2 mg/kg, po measured after 3 hrs | 2012 | Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1
| Discovery of potent and liver-selective stearoyl-CoA desaturase (SCD) inhibitors in an acyclic linker series. |
| AID692228 | Ratio drug uptake in liver to harderian gland of C57BL6 mouse at 10 mg/kg, po measured 6 hrs post dose | 2011 | Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
| Development of a liver-targeted stearoyl-CoA desaturase (SCD) inhibitor (MK-8245) to establish a therapeutic window for the treatment of diabetes and dyslipidemia. |
| AID692214 | Drug uptake in eye of C57BL6 mouse at 10 mg/kg, po measured 6 hrs post dose | 2011 | Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
| Development of a liver-targeted stearoyl-CoA desaturase (SCD) inhibitor (MK-8245) to establish a therapeutic window for the treatment of diabetes and dyslipidemia. |
| AID647858 | Inhibition of SCD1 in rat hepatocytes expressing OATP | 2012 | Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1
| Discovery of potent and liver-selective stearoyl-CoA desaturase (SCD) inhibitors in an acyclic linker series. |
| AID1347170 | Vero cells viability counterscreen for qRT-PCR qHTS assay of selected Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
| Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1347172 | Secondary qRT-PCR qHTS assay for selected Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
| Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |